GERMANTOWN, Md., Sept. 22, 2011 /PRNewswire/ -- SuperNova Diagnostics®, Inc., a privately-held global diagnostics company for human and non-human health applications, today announced that Neil J. Campbell, president and CEO, will be presenting at AdvaMed 2011: The Medtech Conference in Washington, D.C. on September 27, 2011 at 11:00 a.m. in room 204A of the Walter E. Washington Convention Center in Washington, D.C.
The presentation will include an overview of SuperNova's proprietary point-of-care (POC) and point-of-use (POU) diagnostic technology targeting four industry sectors: human health, animal health, industrial and biodefense/biosecurity.
"AdvaMed 2011 is the premier event for investors and leaders in the medical technology industry, and thus is an ideal opportunity for SuperNova to showcase its game-changing, disruptive technology and 'lab-in-the-palm-of-your-hand' diagnostic system," said Mr. Campbell. "With our proprietary AmpCrystal® platform, which provides an array of diagnostic capabilities from patient treatment to pathogen detection, SuperNova has the potential to seize the still largely untapped multi-billion dollar point-of-care and point-of-use diagnostic market."
About SuperNova Diagnostics®, Inc.
SuperNova® is a development-stage diagnostics company with a proprietary platform for conducting diagnostics at the site of interest with point-of-care in human health and point-of-use for non-human health applications. A powerful proprietary nanochemistry, AmpCrystal®, can deliver novel, next generation performance for pathogens, proteins, and directly measure DNA without PCR with ultra-low sensitivity and specificity while not sacrificing a dynamic range of measurements. SuperNova can be utilized in a wide range of diagnostic formats (lateral flow, self-contained cartridges, microtitre, microarrays, closed systems, research products and OEM). SuperNova® — Putting the Laboratory in the Palm of Your Hand®. For additional information, please visit www.supernovadiagnostics.com.
SOURCE SuperNova Diagnostics(R), Inc.